Main content area

COX-2 expression and outcome in canine nasal carcinomas treated with hypofractionated radiotherapy*†

Belshaw, Z., Constantio-Casas, F., Brearley, M.J., Dunning, M.D., Holmes, M.A., Dobson, J.M.
Veterinary and comparative oncology 2011 v.9 no.2 pp. 141-148
carcinoma, dogs, immunohistochemistry, nose, prognosis, prostaglandin synthase, radiotherapy
The expression of cyclooxygenase isoform 2 (COX-2) in canine nasal carcinomas has been well documented. COX-2 expression has proven to be a prognostic factor in several human tumours. The aims of this study were to assess the correlation between immunohistochemical COX-2 expression and prognosis using rhinoscopic biopsies from 42 dogs with nasal carcinomas treated with hypofractionated radiotherapy, and to establish a replicable COX-2 scoring system. Ninety per cent of sections evaluated were COX-2 positive with a mean score of 6.6 (median 8.0; range 0-12). Neither COX-2 expression nor tumour type had a significant correlation with survival. There are likely to be many as yet unidentified variants which contribute to length of survival in dogs with nasal carcinomas. Immunohistochemical COX-2 expression appears unlikely to be of prognostic significance for canine nasal carcinoma.